Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study
Clinical and Molecular Hepatology · 01.07.2026 · 32 (3) · 1364-1378
DOI: 10.3350/cmh.2026.0283 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.07.2026. Verfasst von Kyungyeon Jung und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea. Hauptthemen laut MEDLINE: Ursodeoxycholic Acid, COVID-19, Fatty Liver, Cholagogues and Choleretics. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministry of Food and Drug Safety, National Research Foundation of Korea, KBSMC-SKKU Future Clinical Convergence Academic Research Program.
Abstract (Originalsprache)
Background/Aims: Ursodeoxycholic acid (UDCA) downregulates angiotensin-converting enzyme 2, the cellular entry receptor for SARS-CoV-2, and may reduce acute coronavirus disease 2019 (COVID-19) severity. However, it remains unknown whether UDCA prevents long COVID outcomes in patients with steatotic liver disease (SLD)—a population vulnerable to adverse outcomes. We investigated the association between pre-infection UDCA use and risk of long COVID outcomes in patients with SLD.
Methods
We conducted a nationwide retrospective cohort study using the Korean COVID-19 registry linked to National Health Insurance Service claims data (2019–2022). Patients with SLD (fatty liver index ≥30) who experienced COVID-19 were included. Exposure was defined as at least one UDCA prescription within the 90 days preceding infection. Outcomes of interest were 20 incident long COVID conditions across eight organ systems assessed ≥84 days post-infection. After propensity score (PS) fine stratification, hazard ratios (HR) with 95% confidence intervals (CI) were estimated using Cox regression.
Results
Among 469,108 patients with SLD and COVID-19, 23,560 (5.0%) were UDCA users. After PS fine stratification weighting, UDCA use was not associated with reduced risk for most long COVID outcomes. A protective association was observed for atrial fibrillation (HR 0.51, 95% CI 0.30–0.88), whereas increased risks were found for type 2 diabetes mellitus (HR 1.24, 95% CI 1.09–1.42) and epilepsy (HR 1.69, 95% CI 1.09–2.61).
Conclusions
Pre-infection UDCA use was not associated with reduced risk for most long COVID outcomes in patients with SLD. The observed associations warrant cautious interpretation given potential residual confounding and surveillance bias.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, Korea.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kyung Hee University Hospital, College of Medicine, Kyung Hee University, Seoul, Korea.
- School of Pharmacy, Sungkyunkwan University, Suwon, Korea.
- Centre for Pharmacoepidemiology, Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Förderung
- Ministry of Food and Drug Safety
- National Research Foundation of Korea
- KBSMC-SKKU Future Clinical Convergence Academic Research Program
- Kangbuk Samsung Hospital
- Sungkyunkwan University
- Patient-Centered Clinical Research Coordinating Center
- Ministry of Health and Welfare
Zitieren
APA
Jung, K., Kim, G. A., Woo, J., Youn, J., Choi, E. Y., Bea, S., Choi, A., Kim, J. H., Jang, H., Lee, D. H., Joo, S. K., Shin, J. Y., & Kim, W. (2026). Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study. Clinical and Molecular Hepatology, 32(3), 1364-1378. https://doi.org/10.3350/cmh.2026.0283
Vancouver
Jung K, Kim GA, Woo J, Youn J, Choi EY, Bea S, et al. Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study. Clinical and Molecular Hepatology. 2026;32(3):1364-1378. doi:10.3350/cmh.2026.0283
BibTeX
@article{Jung2026,
author = {Jung, Kyungyeon and Kim, Gi-Ae and Woo, Jieun and Youn, Jin and Choi, Eun-Young and Bea, Sungho and Choi, Ahhyung and Kim, Ju Hwan and Jang, Heejoon and Lee, Dong Hyeon and Joo, Sae Kyung and Shin, Ju-Young and Kim, Won},
title = {Ursodeoxycholic acid and long COVID in steatotic liver disease: a nationwide cohort study},
journal = {Clinical and Molecular Hepatology},
year = {2026},
volume = {32},
number = {3},
pages = {1364--1378},
doi = {10.3350/cmh.2026.0283}
}
EUVIMED